CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-ζ chain expression

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Schüle, Jana M ^a,b   Bergkvist, Leif ^a,b   Håkansson, Leif ^c   Gustafsson, Bertil ^c   Håkansson, Annika ^c  

^a CENTRAL HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MASTECTOMY; PROTEIN LOCALIZATION; SENTINEL LYMPH NODE BIOPSY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE SUBPOPULATION; TUMOR VOLUME;

EID: 18144390241     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-45     Document Type: Article

References (40)

1. Pawelec G, Heinzel S, Kiessling R, Müller L, Ouyang Q, Zeuthen J: Escape Mechanisms in Tumor Immunity: A Year 2000 Update. Critical Reviews in Oncogenesis 2000, 11:97-133.
2. Kurt RA, Urba WJ, Smith JW, Schoof DD: Peripheral T Lymphocytes from Women with Breast Cancer Exhibit Abnormal Protein Expression of Several Signaling Molecules. Int J Cancer 1998, 78:16-20.
3. Lopez CB, Rao TD, Feiner H, Shapiro R, Marks JR, Frey AB: Repression of Interleukin-2 mRNA Translation in Primary Human Breast Carcinoma Tumor-Infiltrating Lymphocytes. Cellular Immunol 1998, 190:141-155.
4. Wolfram RM, Budinsky AC, Brodowicz T, Kubista M, Köstler WJ, Kichler-Lakomi C, Hellan M, Kahlhammer G, Wiltschke C, Zielinski CC: Defective Antigen Presentation Resulting from Impaired Expression of Costimulatory Molecules in Breast Cancer. Int J Cancer 2000, 88:239-244.
5. Reichert TE, Day R, Wagner EM, Whiteside TL: Absent or Low Expression of the Zeta Chain in T Cells at the Tumor Site Correlates with Poor Survival in Patients with Oral Carcinoma. Cancer Res 1998, 58:5344-5347.
6. Matsuda M, Petersson M, Lenkei R, Taupin J-L, Magnusson I, Mellstedt H, Anderson P, Kiessling R: Alterations in the Signal-Transducing Molecules of T Cells and NK Cells in Colorectal Tumor-Infiltrating, Gut Mucosal and Peripheral Lymphocytes: Correlation with the Stage of the Disease. Int J Cancer 1995, 61: 765-772.
7. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activation. Immunology Today 1990, 11:211-216.
8. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunology Today 1994, 15:321-331.
9. Turka LA, Ledbetter JA, Lee K, June CH, Thompson CB: CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature lymphocytes. J Immunol 1990, 144: 1646-1653.
10. Judge TA, Tang A, Turka LA: Immunosuppression through Blockade of CD28:B7-Mediated Costimulatory Signals. Immunol Res 1996, 15:38-49.
11. Rudd C: Upstream-Downstream: CD28 Cosignaling Pathways and T Cell Function. Immunity 1996, 4:527-534.
12. Beecham EJ, Ma Q, Ripley R, Junghans RP: Coupling CD28 Co-Stimulation to Immunoglobulin T-Cell Receptor Molecules: The Dynamics of T-Cell Proliferation and Death. J Immunother 2000, 23:631-642.
13. Chen L, Linsley PS, Hellström KE: Costimulation of T cells for tumor immunity. Immunology Today 1993, 14: 483-486.
14. Van de Corput L, Falkenburg JHF, Kester MGD, Willemze R, Kluin-Nelemans JC: Impaired Expression of CD28 on T Cells in Hairy Cell Leukemia. Clin Immunology 1999, 93:256-262.
15. Rossi E, Matutes E, Morilla R, Owusu-Ankomah K, Heffernan AM, Catovsky D: Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 1996, 10: 494-497.
16. Krüger K, Büning C, Schriever F: Activated T lymphocytes bind in situ to stromal tissue of colon carcinoma but lack adhesion to tumor cells. Eur J Immunol 2001, 31:138-145.
17. Becker JC, Vetter CS, Schrama D, Bröcker E-B, Straten PT: Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node. Eur J Immunol 2000, 30:3699-3706.
18. Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Håkansson L: On down-regulation of the immune response to metastatic malignant melanoma. Cancer Immunol Immunother 1999, 48:253-262.
19. Håkansson A, Håkansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, Bernsen MR: Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28. Cancer Immunol Immunother 2002, 51:499-504.
20. Melichar B, Touskova M, Dvorak J, Jandik P, Kopecky O: The Peripheral Blood Leukocyte Phenotype in Patients with Breast Cancer: Effect of Doxorubicin/Paclitaxel Combination Chemotherapy. Immunopharm Immunotox 2001, 23:163-173.
21. Schüle J, Bergkvist L, Håkansson L, Gustafsson B, Håkansson A: Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res Treat 2002, 74:33-40.
22. Byrt T, Bishop J, Carlin JB: Bias, Prevalence and Kappa. J Clin Epidemiol 1993, 46:423-429.
23. Eck SC, Turka LA: Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4+T cells. Cancer Immunol Immunother 1999, 48:336-341.
24. Deeths MJ, Mescher MF: B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells. Eur J Immunol 1997, 27:598-608.
25. Abe R, Vandenberghe P, Craighead N, Smoot DS, Lee KP, June CH: Distinct Signal Transduction in Mouse CD4+ and CD8+ Splenic T Cells After CD28 Receptor Ligation. J Immunol 1995, 154:985-997.
26. Agrawal SG, Marquet J, Plumas J, Rouard H, Delfau-Larue M-H, Gaulard P, Boumsell L, Reyes F, Bensussan A, Farcet J-P: Multiple costimulatory signals are required for triggering proliferation of T cells from human secondary lymphoid tissue. Int Immunol 2000, 13:441-450.
27. Feuerer M, Rocha M, Bai L, Umansky V, Solomayer E-F, Bastert G, Diel IJ, Schirrmacher V: Enrichment Of Memory T Cells And Other Profound Immunological Changes In The Bone Marrow From Untreated Breast Cancer Patients. Int J Cancer 2001, 92:96-105.
28. Schirrmacher V: T-cell immunity in the induction and maintenance of a tumor dormant state. Sem Cancer Biology 2001, 11:285-295.
29. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP: CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992, 356: 607-609.
30. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM: The critical role of CD28 signaling in the prevention of human T-cell anergy. Res Immunol 1995, 146:140-149.
31. Beverly B, Kang S-M, Lenardo MJ, Schwartz RH: Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 1992, 4:661-671.
32. Vallejo AN, Brandes JC, Weyand CM, Goronzy JJ: Modulation of CD28 Expression: Distinct Regulatory Pathways During Activation and Replicative Senescence. J Immunol 1999, 162:6572-6579.
33. Schmidt D, Goronzy JJ, Weyand CM: CD4+ CD7- CD28- T Cells Are Expanded in Rheumatoid Arthritis and Are Characterized by Autoreactivity. J Clin Invest 1996, 97:2027-2037.
34. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK: Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002, 100:3155-3163.
35. Tuosto L, Acuto O: CD28 affects the earliest signaling events generated by TCR engagement. Eur J Immunol 1998, 28:2131-2142.
36. Rudd C, Janssen O, Cai Y-C, da Silva AJ, Raab M, Prasad KVS: Two-step TCR-zeta/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases. Immunology Today 1994, 15:225-234.
37. Plunkett TA, Miles DW: 13. New biological therapies for breast cancer. Int J Clin Pract 2002, 56:261-266.
38. Hempel P, Muller P, Oruzio D, Behr W, Brockmeyer C, Wochner M, Ehnle S, Riethmuller R, Schlimok G: Combination of high-dose chemotherapy and monoclonal antibody in breast- cancer patients: a pilot trial to monitor treatment effects on disseminated tumor cells. Cytotherapy 2000, 2:287-295.
39. Emtage PCR, Wan Y, Muller W, Graham FL, Gauldie J: Enhanced Interleukin-2 Gene Transfer Immunotherapy of Breast Cancer by Coexpression of B7-1 and B7-2. J Interferon Cytokine Res 1998, 18:927-937.
40. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, Hellström KE: Tumor Immunogenicity Determines the Effect of B7 Costimulation on T Cell-mediated Tumor Immunity. J Exp Med 1994, 179:523-532